Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

SCAI publishes consensus document on PFO closure

An expert consensus statement published by the Society for Cardiovascular Angiography and Interventions (SCAI) offers guidance for the safe and effective use of patent foramen ovale (PFO) closure devices to prevent recurrent stroke.

Thumbnail

Early AVR bests ‘watchful waiting’ in asymptomatic patients

Patients with severe but asymptomatic aortic stenosis have better survival two and three years later if an aortic valve replacement (AVR) is initially recommended instead of a “watchful waiting” approach, according to a single-center study published in The Annals of Thoracic Surgery.

COAPT substudy: MitraClip gives lasting boost to quality of life

NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.

Thumbnail

‘Really not close’: TAVR trumps SAVR in two trials of low-risk patients

NEW ORLEANS — Two trials evaluating transcatheter aortic valve replacement (TAVR) in low-risk patients haven’t just shifted the TAVR versus surgical AVR discussion. They’ve completely flipped it, said experts here at the American College of Cardiology’s scientific sessions.

Thumbnail

Should cardiologists operate sooner for chronic aortic regurgitation?

Patients who received aortic valve repair or replacement (AVR) based on Class II indications fared better than those who underwent surgery for Class I triggers in a single-center study, suggesting earlier intervention may be warranted in asymptomatic individuals with chronic aortic regurgitation.

FDA broadens MitraClip indication to include secondary mitral regurgitation

The FDA has expanded the indication for the MitraClip to include heart failure patients with moderate-to-severe secondary mitral regurgitation, the agency announced March 14. Abbott’s transcatheter mitral valve repair device was approved in 2013, but only for primary mitral regurgitation.

ACC launches Transcatheter Valve Certification for hospitals

The American College of Cardiology (ACC) will begin offering a new Transcatheter Valve Certification to U.S. hospitals in mid-2019, the College announced March 13.

Thumbnail

Edwards invests in 2 companies to boost transcatheter heart treatment portfolio

Edwards Lifesciences has invested $35 million for an exclusive right to acquire Corvia Medical, which is engaged in a U.S. pivotal trial for its InterAtrial Shunt Device (IASD) to treat heart failure.

Displaying 753 - 760 of 874
Design by Adaptive Theme